Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Public ClinicalTrials.gov record NCT05799157. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Study identification
- NCT ID
- NCT05799157
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 153 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 9 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2023 (Actual)
- Primary completion
- Feb 25, 2025 (Actual)
- Completion
- Feb 25, 2025 (Actual)
- Last update posted
- May 8, 2025
2023 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 07 | Fort Smith | Arkansas | 72916 | — |
| Site 16 | San Diego | California | 92123 | — |
| Site 02 | Plainfield | Indiana | 46168 | — |
| Site 13 | Louisville | Kentucky | 40241 | — |
| Site 15 | Baton Rouge | Louisiana | 70809 | — |
| Site 09 | New Brighton | Minnesota | 55112 | — |
| Site 01 | Anderson | South Carolina | 29621 | — |
| Site 06 | Greenville | South Carolina | 29615 | — |
| Site 11 | Knoxville | Tennessee | 37909 | — |
| Site 03 | Arlington | Texas | 76011 | — |
| Site 04 | Austin | Texas | 78759 | — |
| Site 10 | College Station | Texas | 77845 | — |
| Site 12 | Houston | Texas | 77056 | — |
| Site 05 | Pflugerville | Texas | 78660 | — |
| Site 14 | Norfolk | Virginia | 23502 | — |
| Site 08 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05799157, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05799157 live on ClinicalTrials.gov.